Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant chemotherapy versus nivolumab + chemotherapy with postoperative nivolumab in muscle-invasive bladder cancer
MOH_2019-05-06_004883Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of nivolumab in bladder cancer (2 arms), sponsored by Bristol Myers Squibb. Started Dec 2018; status: completed.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on MOH_2019-05-06_004883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-06_004883.